We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ionis (IONS) Beats Earnings & Misses Revenues in Q1
Read MoreHide Full Article
Carlsbad, CA-based Ionis Pharmaceuticals, Inc. (IONS - Free Report) is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies. The company discovers new drugs and out-licenses them to partners for license fees, milestone payments, and royalties. Ionis has partnership agreements with several leading health care companies like Biogen and GlaxoSmithKline among others.
Ionis’ earnings track record has been mixed so far. Over the four trailing quarters, the company posted an average positive earnings surprise of 26.25%, missing estimates in two quarters and beating the same once.
Currently, Ionis has a Zacks Rank #3 (Hold) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Ionis reported a loss of 1 cents including stock based compensation which beat the Zacks Consensus Estimate of loss of 11 cents.
Revenues: Ionis posted revenues of $144.4 million, missing the consensus estimate of $159.81 million. However, it was up 24.7% year over year.
Key Stats: Research, development and patent expenses amounted to $104.1 million, up 25.9% year over year. General and administrative expenses increased almost 219% year over year to $43.7 million on increased costs related to commercialization of Waylivra and Tegsedi, and increase in fees related to in-licensing of Spinraza. Spinraza saw strong uptake with first quarter sales of $364 million.
Share Market Activity: Share price are up 3.3% in pre-market trading.
Ionis Pharmaceuticals, Inc. Price and EPS Surprise
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Ionis (IONS) Beats Earnings & Misses Revenues in Q1
Carlsbad, CA-based Ionis Pharmaceuticals, Inc. (IONS - Free Report) is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies. The company discovers new drugs and out-licenses them to partners for license fees, milestone payments, and royalties. Ionis has partnership agreements with several leading health care companies like Biogen and GlaxoSmithKline among others.
Ionis’ earnings track record has been mixed so far. Over the four trailing quarters, the company posted an average positive earnings surprise of 26.25%, missing estimates in two quarters and beating the same once.
Currently, Ionis has a Zacks Rank #3 (Hold) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Ionis reported a loss of 1 cents including stock based compensation which beat the Zacks Consensus Estimate of loss of 11 cents.
Revenues: Ionis posted revenues of $144.4 million, missing the consensus estimate of $159.81 million. However, it was up 24.7% year over year.
Key Stats: Research, development and patent expenses amounted to $104.1 million, up 25.9% year over year. General and administrative expenses increased almost 219% year over year to $43.7 million on increased costs related to commercialization of Waylivra and Tegsedi, and increase in fees related to in-licensing of Spinraza. Spinraza saw strong uptake with first quarter sales of $364 million.
Share Market Activity: Share price are up 3.3% in pre-market trading.
Ionis Pharmaceuticals, Inc. Price and EPS Surprise
Ionis Pharmaceuticals, Inc. Price and EPS Surprise | Ionis Pharmaceuticals, Inc. Quote
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>